Publication Name	World Journal of Hepatology
Manuscript ID	11646
Country	Spain

Received	2014-05-29 09:28
Peer-Review Started	2014-05-29 21:22
To Make the First Decision	2014-06-27 11:52
Return for Revision	2014-06-27 19:00
Revised	2014-07-14 00:00
Second Decision	2014-08-31 16:55
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-08-31 17:10
Articles in Press	2014-08-31 17:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-27 15:03
Publish the Manuscript Online	2014-11-05 09:07

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Targeting the insulin-like growth factor pathway in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Mónica Enguita-Germán and Puri Fortes
Funding Agency and Grant Number	Funding Agency Grant Number Ministerio de Ciencia e Innovacion BIO2009/09295 Ministerio de Ciencia e Innovacion SAF2012-40003 FEDER funding RNAREG CSD2009-00080 Ministryof Science and Innovation under the programme CONSOLIDER INGENIO 2010
Corresponding Author	Dr. Puri Fortes, Department of Hepatology and Gene Therapy, Center for Applied Medical Research, Pio XII, 55, 31008 Pamplona, Spain. pfortes@unav.es
Key Words	Hepatocellular carcinoma; Insulin; Insulin-like growth factor; Insulin-like growth factor receptor; Therapy; Tyrosine kinase inhibitor; Antibody therapy
Core Tip	It is mandatory to develop alternative therapies for the successful treatment of hepatocellular carcinoma (HCC). One of the key drivers of hepatocarcinogenesis is the insulin-like growth factor (IGF) system. Therefore, several inhibitors of this pathway have been developed and their therapeutic potential is being tested in patients with HCC. However, recent studies suggest that IGF-Ⅱ, a member of the pathway, may be more relevant for hepatocarcinogenesis than its close homologue IGF-Ⅰ. The purpose of this review is to summarize these facts within a detailed description of the IGF axis and the alterations of the pathway that lead to HCC. The strategies designed to target the IGF-Ⅰ?signaling pathway for HCC treatment are also reviewed.
Publish Date	2014-11-05 09:07
Citation	Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6(10): 716-737
URL	http://www.wjgnet.com/1948-5182/full/v6/i10/716.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i10.716

Full Article (PDF)	WJH-6-716.pdf
Full Article (Word)	WJH-6-716.doc
Manuscript File	11646-Review.doc
Answering Reviewers	11646-Answering reviewers.pdf
Copyright License Agreement	11646-Copyright assignment.pdf
Peer-review Report	11646-Peer review(s).pdf
Scientific Misconduct Check	11646-CrossCheck.jpg
Scientific Editor Work List	11646-Scientific editor work list.pdf